A B   D

D   O   R   A   P

A

A   B   ;

(,   ,   ,

),   .

Abstract (continued)

1

90

1, 2021, 16, 2022.

30

3-

6- ( ) 95% C

C

( )

(2).

C

95% C

A - - - ( )

, 6 ,

(31, 2018), . -

(30-), , 6 ,

, . - -

(,

). A -

2

1 90

: (10-17) (18-29);

18 24 25 29 .

( ) -

99

90

10 11 .

40

23 084 (14 444

62.6% ; , 23 4.1) 66 706

(38 446 57.6% ; , 22 4.4 ; , 27 815; ,

10 929;   -   , 27 962),   90.3% (81 097   89 790)   9.7%
(8693   89 790)   (2   ).

                          (♦   ,   **1**). B

Characteristic	Study cohort, unweighted			Inverse probability of treatment weighting[b]		
	No. (%)			Weighted, No (%)		
	Benzodiazepine initiators (n = 23 084)	Comparator group (n = 66 706)	Standardized difference	Benzodiazepine initiators (n = 89 515)	Comparator group (n = 89 814)	Standardized difference
Male	8640 (37.4)	28 260 (42.4)	0.10	36 674 (41.0)	36 812 (41.0)	0.00
Age at treatment initiation, y[c]						
10-17	2001 (8.7)	9730 (14.6)	0.19	11 865 (13.3)	11 713 (13.0)	0.01
18-24	11 424 (49.5)	33 481 (50.2)	0.01	44 712 (49.9)	44 868 (50.0)	0.00
25-29	9659 (41.8)	23 495 (35.2)	0.14	32 938 (36.8)	33 233 (37.0)	0.00
Comorbid psychiatric diagnoses, 1 y						
Anxiety disorder, unspecified						
Recent diagnosis (≤30 d)	6897 (29.9)	10 193 (15.3)	0.36	17 116 (19.1)	17 328 (19.3)	0.00
Past diagnosis only (31-365 d)	1110 (4.8)	3778 (5.7)	0.04	5125 (5.7)	4885 (5.4)	0.01

Characteristic	Study cohort, unweighted			Inverse probability of treatment weighting[b]		
	No. (%)			Weighted, No (%)		
	Benzodiazepine initiators (n = 23 084)	Comparator group (n = 66 706)	Standardized difference	Benzodiazepine initiators (n = 89 515)	Comparator group (n = 89 814)	Standardized difference
Other diagnoses, 1 y						
Musculoskeletal pain	5312 (23.0)	16 206 (24.3)	0.03	21 829 (24.4)	21 566 (24.0)	0.01
Fatigue, malaise	5228 (22.6)	12 528 (18.8)	0.10	17 871 (20.0)	17 855 (19.9)	0.00
Migraine, headache	4112 (17.8)	11 590 (17.4)	0.01	16 017 (17.9)	15 781 (17.6)	0.01

A........ ....

18   29   ,   6-

(   )   0.9%   0.6%   .

,

(-   :   , 1.63

95% C , 1.25-2.12) (3).   18   24   25   29   ,
   (-   :   , 1.62 95% C , 1.20-2.18   1.52 95% C , 0.87-
2.66 ,   ).

A

6,45

. A

46

47

A

2,4

. B   6-

A :   A. B   ,   , C   ,
C   A   ,   , 112   ,   422,   B   ,
08901 (.   @   .   ).

A . **A**   : C   ,   ,
C   A   ,   B   ,   (B   ,   );
B   ,   ,   ,   (B   );
A   ,   ,   ,
,   (   );   , C

46 46AutObisin9(Adminis)funding3 1 Tf 10.16tS7p53(4)341.7viyhi8son);   AutConf ScienceuPhati.6(earch,)-u4.9(s-Pha)9.8(D.9(.6(u(earch,)-3 1 Tf 10.1615 03TJ073T)9.8

24.   A   .   . A   10, 2020.